NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery. Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationships with ineligible companies to disclose.

Juskaran S. Chadha, DO, MBA
Carey B. Deacon
Deborah A. Freedman-Cass, PhD
Patrick J. Loehrer, MD
Brock O'Neil, MD
Daniel A. Roberts, MD
Bryan J. Schneider, MD

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated. 

Thomas W. Flaig, MD
Agensys, Inc.: Grant/Research Support
Astellas Pharma US, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Aurora Oncology: Equity Interest/Stock Options; Intellectual Property Rights
Bristol Myers Squibb: Grant/Research Support
Criterium: Consulting Fee; Scientific Advisor
Genentech, Inc.: Grant/Research Support
Janssen Pharmaceutica Products, LP: Grant/Research Support; Scientific Advisor
Merck & Co., Inc.: Grant/Research Support
Myovant Sciences GmbH/Sumitomo Pharma Co. Ltd: Grant/Research Support
sanofi-aventis U.S.: Grant/Research Support
SeaGen: Grant/Research Support

Renuka V. Iyer, MD (Fellows Program Moderator) 
AstraZeneca Pharmaceuticals LP: Grant/Research Support; Honoraria
Boehringer Ingelheim GmbH: Honorarium
Exelixis Inc.: Honoraria
Genentech, Inc.: Scientific Advisor
Merck & Co., Inc.: Grant/Research Support 

Shikha Jain, MD
BeiGene: Product/Speakers Bureau 
Jazz Pharmaceuticals Inc.: Product/Speakers Bureau
Novartis Pharmaceuticals Corporation: Product/Speakers Bureau
Pfizer Inc.: Product/Speakers Bureau

Timothy Kubal, MD, MBA
Alexion Pharmaceuticals, Inc.: Scientific Advisor
Novartis Pharmaceuticals Corporation: Consulting Fee
sanofi-aventis U.S.: Consulting Fee

Kevin P. Labadie, MD
Johnson & Johnson: Consulting Fee 

Zhuoyan (Yan) Li, MD
AstraZeneca Pharmaceuticals LP: Consulting Fee; Product/Speakers Bureau
Bristol Myers Squibb: Consulting Fee
Takeda Pharmaceuticals North America, Inc.: Consulting Fee

Gregory J. Riely, MD, PhD
Amgen Inc.: Grant/Research Support
Bristol Myers Squibb: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Pfizer Inc.: Grant/Research Support
Roche Laboratories, Inc.: Grant/Research Support 

Michael B. Streiff, MD
CSL Bhering: Consulting Fee; Scientific Advisor 
Genentech, Inc.: Grant/Research Support
Grifols, S.A.: Grant/Research Support
Regeneron Pharmaceuticals, Inc.: Grant/Research Support 

NCCN Staff Disclosures

None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.